Preamendment Class III devices
This article was originally published in The Gray Sheet
FDA extends to Sept. 6 the comment period on its proposed schedule for calling for premarket approval applications for 117 preamendment Class III devices. The Health Industry Manufacturers Association had requested the 30-day extension
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.